Causal associations of sarcopenia‐related traits with cardiometabolic disease and Alzheimer's disease and the mediating role of insulin resistance: A Mendelian randomization study

Chaojie Ye,Lijie Kong,Yiying Wang,Jie Zheng,Min Xu,Yu Xu,Mian Li,Zhiyun Zhao,Jieli Lu,Yuhong Chen,Weiqing Wang,Guang Ning,Yufang Bi,Tiange Wang

DOI: https://doi.org/10.1111/acel.13923

IF: 11.005

2023-07-06

Aging Cell

Abstract:This study shed light on the causal influences of sarcopenia‐related traits on major cardiometabolic diseases and Alzheimer's disease independent of body fat and physical activity and the mediating role of insulin resistance in the association pathway. These findings support improving sarcopenia as encouraging precautions against major cardiometabolic diseases and Alzheimer's disease, with a particular emphasis on insulin resistance as a target in lowering sarcopenia‐related cardiometabolic risk. The causal influence of sarcopenia on cardiometabolic disease and Alzheimer's disease and whether and to what extent insulin resistance plays a mediating role therein were unclear. We performed two‐step, two‐sample Mendelian randomization applying genetic instruments of sarcopenia‐related traits based on GWASs from the UK Biobank (up to 461,026 European participants) to examine their causal associations with six cardiometabolic diseases and Alzheimer's disease extracted from large‐scale European descent GWASs with adjustment for body fat percentage and physical activity, and to assess proportions of the causal effects mediated by insulin resistance. Genetic instruments of insulin resistance were derived from the GWASs by Meta‐Analyses of Glucose and Insulin‐related traits Consortium and Global Lipids Genetics Consortium. Each 1‐SD lower grip strength, appendicular lean mass (ALM) and whole‐body lean mass (WBLM), as well as lower walking pace, were causally associated with higher risks of diabetes (odds ratio [OR] range: 1.20 [95% confidence interval: 1.10–1.32] for ALM to 2.30 [1.14–4.68] for walking pace), nonalcoholic fatty liver disease ([NAFLD], 1.33 [1.08–1.64] for ALM to 2.30 [1.02–5.18] for grip strength), hypertension (1.12 [1.05–1.20] for ALM to 4.43 [2.68–7.33] for walking pace), coronary heart disease ([CHD], 1.20 [1.13–1.27] for ALM to 2.73 [1.84–4.05] for walking pace), myocardial infarction ([MI], 1.18 [1.11–1.25] for ALM to 2.47 [1.63–3.73] for walking pace), small vessel stroke (1.25 [1.15–1.37] for ALM to 1.29 [1.10–1.52] for WBLM), and Alzheimer's disease (1.10 [1.05–1.15] for ALM to 1.28 [1.19–1.38] for WBLM). These causal associations were largely independent of body fat percentage and physical activity. Insulin resistance mediated 16%–34% of the effect of grip strength and 7%–28% of the effect of ALM on diabetes, NAFLD, hypertension, CHD, and MI. The direct effect of WBLM on diabetes diminished toward null with adjustment for insulin resistance. We found no evidence that insulin resistance was on the causal pathways from walking pace to the studied disease outcomes. Causal findings from the inverse‐variance weighted method were validated by sensitivity analyses. These findings support improving sarcopenia‐related traits as precautions against major cardiometabolic diseases and Alzheimer's disease, with particular emphasis on insulin resistance as a target in the intervention of sarcopenia‐related cardiometabolic risk.

cell biology,geriatrics & gerontology